Skip to main content

Advertisement

Table 1 Demographic s and clinical characteristics of Sample

From: A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD

   NS2359 Placebo
Subjects Randomised   63 63
Gender Male 47 (74.6%) 42 (66.7%)
  Female 16 (25.4%) 21 (33.3%)
Age 18–25 13 (20.6%) 13 (20.6%)
  Median (Range) 35.0 (18.8–54.1) 35.2 (19.0–51.1)
Origin Caucasian 51 (81.0%) 54 (85.7%)
  African American 4 (6.3%) 3 (4.8%)
  Asian 3 (4.8%) 0 (0.0%)
  Other 5 (7.9%) 6 (9.5%)
Previous Treatment for ADHD Yes 17 (27.0%) 18 (28.6%)
  No 46 (73.0%) 45 (71.4%)
ADHD Subgroup Inattentive 17 (27.0%) 29 (46.0%)
  Hyperactive/Impulsive 0 (0.0%) 1 (1.6%)
  Combined 38 (60.3%) 32 (50.8%)
  Not Classified 8 (12.7%) 1 (1.6%)
Weight (kg) Median (range) 80.3 (54.9–142.9) 78.9 (48.5–133.4)
Height (cm) Median (range) 173 (152–197) 175 (151–188)
Smoker Yes 16 (25.4%) 15 (23.8%)
  Former 9 (14.3%) 17 (27.0%)
  No 38 (60.3%) 31 (49.2%)
Alcohol Yes, Average 53 (84.1%) 58 (92.1%)
Consumption Yes, Excessive 0 (0.0%) 0 (0.0%)
  No 10 (15.9%) 5 (7.9%)
Hamilton Depression score Median (Range) 3.0 (0.0–15.0) 4.0 (0.0–12.0)
CGI Severity of Illness 4 – Moderately 30 (47.6%) 29 (46.0%)
  5 – Markedly 28 (44.4%) 31 (49.2%)
  6 – Severely 4 (6.3%) 3 (4.8%)
  7 – Extremely 1 (1.6%) 0 (0.0%)